The results of this study confirmed initial observations, showing that the hypomethylating agent and venetoclax combination as salvage setting is of limited efficacy, with the possible exception of AML patients with IDH1/IDH2 mutations [169]. This evidence concerns the gene IDH1 and acute myeloid leukemia.